Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A deep learning model to dynamically predict cancer-associated thromboembolism in large-scale healthcare systems.

NPJ digital medicine·2026
Same author

Endothelial cell expression of STING<sup>V154M</sup>: Gain-of-function mutation delays the resolution of UVB-induced skin injury.

The Journal of investigative dermatology·2026
Same author

Tryptophan metabolism reprogramming potentially contributes to the prothrombotic milieu in mice and humans with SARS-CoV-2.

Blood vessels, thrombosis & hemostasis·2026
Same author

Hematopoietic JAK2V617F mutation-induced reprogramming of blood and bone marrow megakaryocytes.

Blood advances·2026
Same author

Piezo1 Mechanosensor Expression in Rare Hematopoietic Cells Controls Systemic Inflammatory Response in Mice.

Cells·2025
Same author

A panel of plasma proteins associated with venous thromboembolism in patients with prostate cancer.

Cancer biomarkers : section A of Disease markers·2025

Related Experiment Video

Updated: May 24, 2026

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
08:30

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice

Published on: April 19, 2011

A2 adenosine receptors and vascular pathologies.

Hillary A Johnston-Cox1, Milka Koupenova, Katya Ravid

  • 1Department of Medicine, Boston University School of Medicine, MA 02118, USA.

Arteriosclerosis, Thrombosis, and Vascular Biology
|March 17, 2012
PubMed
Summary

Inflammation impacts cardiovascular disease. Adenosine, a metabolite, influences this via A2A and A2B receptors, offering therapeutic targets for vascular conditions.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
07:55

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice

Published on: May 5, 2011

Related Experiment Videos

Last Updated: May 24, 2026

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice
08:30

Use of a Hanging Weight System for Coronary Artery Occlusion in Mice

Published on: April 19, 2011

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice
07:55

Pressure Controlled Ventilation to Induce Acute Lung Injury in Mice

Published on: May 5, 2011

Area of Science:

  • Cardiovascular Science
  • Molecular Biology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a major cause of death and illness, significantly influenced by inflammatory processes.
  • The metabolite adenosine levels rise during physiological stress like inflammation or hypoxia.
  • Adenosine exerts diverse effects through four receptor subtypes: A1, A2A, A2B, and A3.

Purpose of the Study:

  • To review the specific roles and shared mechanisms of A2A and A2B adenosine receptors in vascular disease.
  • To elucidate the contribution of these receptors to the pathogenesis of cardiovascular conditions.

Main Methods:

  • Literature review focusing on studies investigating adenosine receptors in vascular disease.
  • Analysis of research detailing the signaling pathways and physiological effects of A2A and A2B receptors.

Main Results:

  • A2A and A2B adenosine receptors play distinct yet interconnected roles in regulating vascular inflammation and pathology.
  • These receptors modulate key processes in vascular disease, including endothelial function, immune cell recruitment, and smooth muscle cell proliferation.

Conclusions:

  • Targeting A2A and A2B adenosine receptors presents a promising therapeutic strategy for managing and preventing cardiovascular diseases.
  • Further understanding of these receptors' mechanisms is crucial for developing effective treatments for vascular conditions.